 |
|
|
| |
EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN
PATIENTS WITH HCV GENOTYPE 5 OR 6 INFECTION: THE ENDURANCE-5, 6 STUDY
|
| |
| |
Reported by Jules Levin;
EASL 2018 April 13 Paris, Franceo
Tarik Asselah1, Tuan Nguyen2, Betty Yao3, Florence Wong4, Adam Mahomed5, Seng Gee Lim6, Samuel S Lee7, Armand Abergel8, Joe Sasadeusz9, Katia Alves3, Preethi Krishnan3, Zhenzhen Zhang3, Ariel Porcalla3, Roger Trinh3, Edward Gane10
1Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Université Paris Diderot, Department of Hepatology, AP-HP Hôpital Beaujon, Clichy, France; 2. Research and Education, Inc., San Diego, California, United States; 3. AbbVie Inc., North Chicago, Illinois, United States; 4. Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada; 5. Faculty of Health Sciences, University of Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital, Department of Gastroenterology and Hepatology, South Africa; 6. Division of Gastroenterology and Hepatology, National University Health System, Singapore; 7. University of Calgary, Calgary, AB, Canada; 8. CHU Estaing, Clermont Ferrand, France; 9. Royal Melbourne Hospital, Melbourne, Australia; 10. Auckland Clinical Studies, Auckland, New Zealand
|
| |
|
|
|
|
|
